Brief: Humanigen Aligns With FDA On Potential Registration Phase 3 Study For Lenzilumab With CAR-T

Humanigen

10/01/2022 11:49

Jan 10 (Reuters) - Humanigen Inc  HGEN.O :
    * HUMANIGEN ALIGNS WITH FDA ON POTENTIAL REGISTRATION PHASE 3 STUDY FOR
LENZILUMAB
WITH CAR-T
    * HUMANIGEN INC - SHIELD TRIAL WILL BUILD ON POSITIVE RESULTS FROM ZUMA-19
STUDY
    * HUMANIGEN INC - RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SHIELD TRIAL
TO
COMMENCE IN H1 2022
    * HUMANIGEN - PRIMARY ENDPOINT OF SHIELD WILL FOCUS ON DEMONSTRATING A
SIGNIFICANT
IMPROVEMENT IN NEUROTOXICITY ASSOCIATED WITH BOTH YESCARTA & TECARTUS
    * HUMANIGEN INC - WILL ALSO SEEK TO DEMONSTRATE BENEFICIAL IMPACT THAT
LENZILUMAB
MAY HAVE ON HEALTHCARE RESOURCE UTILIZATION
    * HUMANIGEN INC - SHIELD STUDY WILL BEGIN RECRUITMENT IN H1 2022, WITH
PRELIM DATA
POTENTIALLY BEING SHARED IN DECEMBER 2022

Source text for Eikon:  ID:nBw1Wrgn1a 
Further company coverage:  HGEN.O